HC Wainwright Has Negative Outlook for MAZE FY2026 Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE) – HC Wainwright cut their FY2026 EPS estimates for Maze Therapeutics in a research report issued on Tuesday, November 10th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings of ($2.86) per share for the year, down from their prior estimate of ($2.63). HC Wainwright has a “Buy” rating and a $110.00 price target on the stock. The consensus estimate for Maze Therapeutics’ current full-year earnings is ($2.70) per share. HC Wainwright also issued estimates for Maze Therapeutics’ Q4 2026 earnings at ($0.83) EPS, Q1 2027 earnings at ($0.80) EPS, Q2 2027 earnings at ($0.81) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.72) EPS, FY2027 earnings at ($3.15) EPS, FY2028 earnings at ($2.55) EPS, FY2029 earnings at ($2.39) EPS and FY2030 earnings at ($2.52) EPS.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.01).

MAZE has been the subject of a number of other reports. Citigroup began coverage on Maze Therapeutics in a report on Wednesday, September 23rd. They set a “buy” rating and a $50.00 price objective for the company. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Canaccord Genuity Group assumed coverage on shares of Maze Therapeutics in a research note on Monday, October 19th. They set a “buy” rating and a $75.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday, September 21st. Three investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $63.91.

Maze Therapeutics Stock Performance

Shares of MAZE opened at $36.73 on Thursday. The firm’s 50 day moving average price is $28.32 and its two-hundred day moving average price is $31.63. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 14.14. Maze Therapeutics has a twelve month low of $21.95 and a twelve month high of $53.65. The firm has a market cap of $2.04 billion, a P/E ratio of -13.86 and a beta of 2.04.

Institutional Investors Weigh In On Maze Therapeutics

A number of large investors have recently added to or reduced their stakes in MAZE. Bessemer Group Inc. grew its stake in Maze Therapeutics by 3.0% during the third quarter. Bessemer Group Inc. now owns 496,253 shares of the company’s stock worth $13,488,000 after buying an additional 14,463 shares in the last quarter. Jefferies Financial Group Inc. acquired a new position in Maze Therapeutics in the 3rd quarter worth about $1,519,000. Alps Advisors Inc. raised its holdings in Maze Therapeutics by 31.5% in the 3rd quarter. Alps Advisors Inc. now owns 73,574 shares of the company’s stock valued at $2,000,000 after buying an additional 17,604 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Maze Therapeutics during the third quarter valued at $77,000. Finally, Profund Advisors LLC increased its holdings in Maze Therapeutics by 410.5% in the third quarter. Profund Advisors LLC now owns 56,281 shares of the company’s stock valued at $1,530,000 after purchasing an additional 45,256 shares during the period.

Insider Buying and Selling at Maze Therapeutics

In related news, CMO Harold Bernstein sold 16,141 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $26.93, for a total value of $434,677.13. Following the transaction, the chief marketing officer directly owned 16,141 shares in the company, valued at approximately $434,677.13. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $32.07, for a total transaction of $240,525.00. Following the transaction, the insider directly owned 32,316 shares in the company, valued at approximately $1,036,374.12. This represents a 18.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 176,849 shares of company stock worth $4,741,878. Insiders own 5.30% of the company’s stock.

Latest Maze Therapeutics News

Here’s some of the latest news about MAZE:

• Positive Sentiment: Wedbush reportedly expects MAZE shares to rise, adding a bullish analyst view. Maze Therapeutics stock price expected to rise, Wedbush analyst says
• Positive Sentiment: Despite reporting a wider Q3 2026 loss, Maze’s HORIZON trial was characterized as delivering positive news; the article does not provide further trial details. Maze Therapeutics Q3 2026: Wider Loss, But HORIZON Trial Delivers
• Negative Sentiment: HC Wainwright cut its EPS forecasts across 2026–2030 and several 2027 quarters, projecting larger losses than previously expected. It nevertheless kept its “Buy” rating and $110 price target. The reduced estimates are a potential near-term headwind. Maze Therapeutics analyst estimates and ratings

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for people with serious diseases. Its research uses human genetics and functional genomics to identify disease-related biological pathways and potential drug targets. The company’s Maze Compass platform is designed to connect genetic insights with biological research to guide drug discovery and development. Its investigational programs have included approaches for APOL1-mediated kidney disease and Pompe disease; these are not marketed treatments.